CompanyGraph
The Cooper Companies, Inc.
COO · United States
Makes the only FDA-approved hormone-free copper IUD and contact lenses with a unique FDA-approved claim for reducing dryness.
The Cooper Companies holds two FDA approvals that function more like regulatory monopolies than product advantages: the Proclear contact lens line carries a specific dryness-reduction claim tied to a phosphorylcholine polymer that mimics cell membranes, and Paragard is the only hormone-free copper IUD approved in the United States. A competitor cannot copy either position with money alone — matching the Proclear claim requires licensing that specific polymer or running fresh clinical studies against a different molecule, and a rival copper IUD would need to complete its own FDA approval from scratch, with either path taking eighteen to twenty-four months regardless of how much is spent. On the patient side, switching away from Proclear means an eye care practitioner must refit the patient over six to eight weeks, and switching away from Paragard requires a removal procedure followed by a new consultation, so both product lines are sticky once a patient is on them. The one thread that could unravel this structure is the phosphorylcholine supply chain: if the polymer supplier exits or strikes an exclusive deal with a competitor, the approved dryness claim suspends with it, and the Proclear line loses the one thing capital cannot replicate.
How does this company make money?
The company sells disposable contact lenses to distributors and eye care practitioners on a per-unit basis. Daily lenses generate recurring purchases every month as wearers replace them. Specialty lenses — toric lenses for astigmatism and multifocal lenses for presbyopia — sell at higher prices than standard spherical lenses, so the mix of products sold affects how much revenue each sale generates.
What makes this company hard to replace?
When a patient switches contact lens brands, an eye care practitioner must conduct a new fitting because different brands use different base curves and materials — a process that typically takes six to eight weeks. Switching away from Paragard requires a medical procedure to remove the device, after which a patient must go through consultation and planning before starting an alternative, making the switch dependent on appointment availability and personal contraceptive timelines.
What limits this company?
Every new lens material or shape requires its own FDA review, which takes 18 to 24 months and cannot be shortened no matter how much money is spent. That fixed timeline means the company is always at least a year and a half behind when responding to new lens technologies or materials developed by rivals.
What does this company depend on?
The company cannot operate without hydrogel and silicone hydrogel polymer formulations for making lenses, the phosphorylcholine polymer supplier specifically, copper wire that meets biocompatibility standards for Paragard production, automated lens molding equipment running under cleanroom conditions, and FDA 510(k) clearance pathways that legally allow the products to be sold.
Who depends on this company?
Eye care practitioners rely on the company's toric and multifocal lenses — which come in multiple base curves — to fit patients with astigmatism and age-related vision changes. If those lenses disappeared, practitioners would have fewer fitting options and some patients could not be adequately corrected. Women who need long-term contraception without hormones depend entirely on Paragard, because it is the only such device approved in the United States. Contact lens wearers with presbyopia who use multifocal lens designs would also lose access to those specific products.
How does this company scale?
Automated molding equipment can be run for more hours or with additional machines to produce more lenses at relatively low added cost, so daily production volume can grow without rebuilding the manufacturing process. What does not scale is the regulatory side: every new lens material or geometry still requires separate FDA validation, clinical studies, and practitioner training programs that take the same 18 to 24 months regardless of how large the company grows.
What external forces can significantly affect this company?
Aging populations are increasing the number of people who need multifocal lenses for presbyopia, which could expand demand. Changes to healthcare reimbursement rules could affect how easily patients can access and afford Paragard. Disruptions to specialty chemical supply chains — particularly those that provide the polymer formulations used in lens manufacturing — could interrupt production at any point.
Where is this company structurally vulnerable?
If the supplier of the phosphorylcholine polymer stopped selling it, sold it exclusively to a competitor, or if the FDA required the dryness-reduction claim to be re-validated under updated safety standards, the Proclear line would lose the one thing competitors cannot replicate. Without that approved claim, Proclear becomes a lens like any other.